Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Dae Ho Lee
Endocrinol Metab. 2020;35(2):243-259.   Published online 2020 Jun 24     DOI:
Citations to this article as recorded by Crossref logo
MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
Ying-Xin Xian, Jian-Ping Weng, Fen Xu
Chinese Medical Journal.2021; 134(1): 8.     CrossRef
Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review
Jenny Lee, Yasaman Vali, Jerome Boursier, Rene Spijker, Quentin M. Anstee, Patrick M. Bossuyt, Mohammad H. Zafarmand
Liver International.2021; 41(2): 261.     CrossRef
Serum syndecan‐4 is associated with nonalcoholic fatty liver disease
Shu Jing Xia, Li Zhong Tang, Wen Hua Li, Zhao Shan Xu, Li Li Zhang, Feng Gan Cheng, Hong Xia Chen, Zi Hua Wang, Yu Cheng Luo, An Na Dai, Jian Gao Fan
Journal of Digestive Diseases.2021; 22(9): 536.     CrossRef
Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
Endocrinology and Metabolism.2021; 36(4): 823.     CrossRef